Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)
- on behalf of the ELM-2 Investigators
- Sungkyunkwan University
- Seoul National University
- The Catholic University of Korea
- Hospital Universitario La Fe
- Medical University of Łódź
- National University Hospital
- University of Melbourne
- Tianjin Medical University
- Fudan University
- Zhengzhou University
- the First Affiliated Hospital of Zhengzhou University
- Nantes University
- Dong-A University
- Singapore General Hospital
- Vall d'Hebron Institute of Oncology
- Koo Foundation Sun Yat-Sen Cancer Center
- University of Iowa
- Hospital Universitario Son Espases
- Regeneron Pharmaceuticals, Inc.
- Ltd.
- Maria Sklodowska-Curie Institute of Oncology
- Tufts Medical Center
- University of Texas Southwestern Medical Center
- Kosair Children's Hospital
- Wake Forest University
- Mayo Clinic Rochester, MN
- Beth Israel Deaconess Medical Center
- Rush University Medical Center
- Hackensack Meridian Health
- Cleveland Clinic Foundation
- OU Health-Stephenson Cancer Center
- Stony Brook University
- Cornell University
- Cardiff & Vale University Health Board
- University Hospitals Plymouth NHS Trust
- Royal Cornwall Hospitals NHS Trust
- Kings College Hospital
- Royal Marsden NHS Foundation Trust
- Chang Gung Memorial Hospital
- National Taiwan University
- China Medical University Taichung
- National Cheng Kung University
- Hospital de Sant Pau
- University of Barcelona
- Hospital Clinic Barcelona
Research output: Contribution to journal › Comment/debate
1
Link opens in a new tab
Scopus
citations